🔗 Share this article

Former Prime Minister Sunak has strengthened his appeal for a specialized examination protocol for prostate gland cancer.

In a recent interview, he stated being "certain of the urgency" of implementing such a system that would be affordable, feasible and "preserve numerous lives".

His statements come as the National Screening Advisory Body reevaluates its ruling from the previous five-year period not to recommend routine screening.

Media reports indicate the body may uphold its existing position.

Athlete Adds Support to Movement

Champion athlete Sir Hoy, who has late-stage prostate gland cancer, advocates for younger men to be checked.

He proposes decreasing the minimum age for requesting a prostate-specific antigen laboratory test.

At present, it is not automatically provided to healthy individuals who are under 50.

The PSA test remains controversial though. Readings can increase for reasons other than cancer, such as infections, resulting in false positives.

Skeptics contend this can lead to unwarranted procedures and side effects.

Targeted Testing Proposal

The suggested testing initiative would focus on men aged 45–69 with a hereditary background of prostate cancer and African-Caribbean males, who face twice the likelihood.

This demographic includes around 1.3 million men in the Britain.

Organization calculations propose the initiative would necessitate twenty-five million pounds a year - or about £18 per patient - similar to bowel and breast cancer screening.

The assumption envisions 20% of eligible men would be invited each year, with a seventy-two percent uptake rate.

Clinical procedures (scans and biopsies) would need to increase by 23%, with only a moderate growth in healthcare personnel, as per the study.

Medical Professionals Reaction

Several clinical specialists remain uncertain about the value of testing.

They assert there is still a chance that men will be medically managed for the disease when it is not absolutely required and will then have to experience side effects such as incontinence and impotence.

One prominent urological specialist commented that "The challenge is we can often detect disease that might not necessitate to be managed and we potentially create harm...and my concern at the moment is that harm to benefit ratio needs adjustment."

Individual Perspectives

Individual experiences are also shaping the discussion.

A particular example features a 66-year-old who, after asking for a PSA test, was detected with the disease at the time of fifty-nine and was advised it had spread to his pelvis.

He has since received chemotherapy, radiotherapy and hormonal therapy but cannot be cured.

The patient supports examination for those who are potentially vulnerable.

"That is very important to me because of my sons – they are in their late thirties and early forties – I want them checked as promptly. If I had been screened at 50 I am confident I would not be in the situation I am today," he said.

Future Actions

The Screening Advisory Body will have to evaluate the evidence and arguments.

Although the recent study says the consequences for personnel and capacity of a examination system would be feasible, some critics have argued that it would divert diagnostic capabilities from patients being managed for different health issues.

The ongoing debate underscores the complex trade-off between early detection and likely overtreatment in prostate gland cancer treatment.